Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCH Grid Technique Injections for Cellulite with Laxity
NCT04580303Phase 2Completed
- Sponsor
- Endo International plc
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of collagenase clostridium histolyticum in cellulite (4 arms), sponsored by Endo International plc. Primary endpoint: Percentage of 1-Level Responders on Investigator-Global Aesthetic Improvement Scale at Day 180. Started Oct 2020; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
cellulite
Beyond the preview
Go deeper on NCT04580303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580303.